Biogen reported disappointing results Sunday from a late-stage clinical trial involving its experimental treatment for a rare, genetically defined form of amyotrophic lateral sclerosis, or Lou Gehrig’s disease.
In the Phase 3 study, the Biogen drug called tofersen failed to slow the neurologic and functional decline of ALS patients compared to a placebo. The drug showed some improvements on other measures of disease progression, the company said, although interpreting those secondary results is challenging because the study’s main goal was not met.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
